AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT
EXHIBIT
10.29
Executive
AMENDMENT NO. 1 TO
EMPLOYMENT AGREEMENT
EMPLOYMENT AGREEMENT
This Amendment No. 1 (this “Amendment”), dated as of May 31, 2007, to the Employment Agreement
(“Agreement”), dated as of January 1, 2004, between Xxxxxxx Xxxxxxx (“Employee”) and ADVANCED
BIOTHERAPEUTICS, INC. (“Employer”).
WHEREAS, Employee is employed by Advanced Biotherapeutics, Inc., a wholly-owned subsidiary of
Athersys, Inc. (“Athersys”); and
WHEREAS, Employer and Employee wish to amend the Agreement in connection with the planned
merger (the “Merger”) of Athersys with a wholly-owned subsidiary of a shell company (as such term
is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”)) that has a class of equity securities registered under Section 12 of the Exchange Act
(“PubCo”); and
WHEREAS, concurrent with and as a condition to the closing of the Merger, PubCo intends to
conduct a private placement transaction pursuant to Regulation D promulgated under the Securities
Act of 1933, as amended, whereby PubCo will receive gross proceeds of at least $40 million as
consideration for the issuance of its equity securities (the “Offering”).
NOW, THEREFORE, the parties hereto, intending to be legally bound, agree as follows:
1. Notwithstanding anything to the contrary in the Agreement, neither the consummation of the
Merger nor the consummation of the Offering shall be deemed a “Change in Control” for purposes of
the Agreement.
2. Upon consummation of the Offering, Athersys shall be deemed to have successfully completed
Milestone A described on Exhibit A to the Agreement and Employee shall be entitled to a $50,000
bonus, and all other milestone payments on Exhibit A to the Agreement will waived by Employee and
be deleted from the Agreement.
3. This Amendment and the Agreement shall bind and inure to the benefit of and be enforceable
by Employee, Employer and their respective heirs, executors, personal representatives, successors
and assigns, except that neither party may assign any rights or delegate any obligations hereunder
without the prior written consent of the other party. Notwithstanding anything to the contrary in
the foregoing, Employee hereby consents to the assignment by Employer of all of its rights and
obligations hereunder to any successor to Employer by merger or consolidation or purchase of all or
substantially all of Employer’s assets, including, without limitation, any deemed assignment that
occurs as a result of the consummation of the Merger.
1 of 3
4. This Amendment may be executed in two or more counterparts, each of which constitutes an
original, and all of which taken together shall constitute one and the same Amendment. It is
understood that all parties need not sign the same counterpart. In the event that any signature is
delivered by facsimile transmission or by email delivery of a “.pdf” format data file, such
signature shall create a valid and binding obligation of the party executing (or on whose behalf
such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature
page were an original thereof.
5. The validity, interpretation, construction and performance of this Amendment will be
governed by the laws of the State of Ohio without regard to its conflicts of law principles.
6. Capitalized terms used but not otherwise defined herein have the meanings set forth in the
Agreement.
2 of 3
IN WITNESS WHEREOF, each of the parties has executed this Amendment as of the day and year
first written above.
Xxxxxxx Xxxxxxx | Advanced Biotherapeutics, Inc. | |||||||||||||
/s/ Xxxxxxx Xxxxxxx | By: | /s/ Gil Van Bokkelen | ||||||||||||
Name: Title: |
Gil Van Bokkelen Chief Executive Officer |
|||||||||||||
Date
|
Date | |||||||||||||
Acknowledged By: | ||||||||||||||
Athersys, Inc. | ReGenesys, LLC | |||||||||||||
By: | /s/ Xxxx Xxxxxxxxxx | By: | /s/ Gil Van Bokkelen | |||||||||||
Name: Title: |
Xxxx Xxxxxxxxxx Executive Vice President & CSO |
Name: Title: |
Gil Van Bokkelen President |
|||||||||||
Date
|
Date |
3 of 3